Go to Page # Page of 13

Safety Evaluation of 2

 Maja Janas PhD
  7th-Dec-2018
Description: This presentation provides information about the Safety Evaluation's Important factors include the ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
Views: 2502
Domain: Medical
Category: Biotech/Pharma
Contents:
Safety Evaluation of 2'-Deoxy-2'-Fluoro-Modified
Nucleotides in GalNAc-siRNA Conjugates
Maja Janas, PhD, DABT
Principal Scientist, Early Development
14th Annual Meeting of the OTS
October 3rd, 2018
1

CONFIDENTIAL

© 2018 Alnylam Pharmaceuticals, Inc.

Alnylam Forward Looking Statements
This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities ... See more

Recent Presentations

...
22 February, 2019
21 February, 2019

ML: Hukou System and Health Outcomes

China’s Hukou reform is a move in the right direction. Pilot programs in 29 provinces are helping to raise awareness about the necessity to eliminate barriers to health access.

...
20 February, 2019